Rising Gastrointestinal Bleeding Mortality in the DOAC Era: A Population-Based Real-World Analysis of U.S. National Death Records, 2007–2020

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: The widespread adoption of direct oral anticoagulants (DOACs) has transformed anticoagulation management in the United States; however, the population-level effects on gastrointestinal (GI) bleeding mortality remain unclear. Methods: We conducted a population-based, observational study using interrupted time series (ITS) analysis of U.S. national death records (CDC WONDER, 2007–2020). GI bleeding-related deaths were identified using prespecified ICD-10 codes and further restricted to decedents with clinical indications for anticoagulation (atrial fibrillation, pulmonary embolism, or deep vein thrombosis). Trends in age-adjusted GI bleeding mortality and anticoagulant utilization were assessed. Exposure-adjusted mortality among estimated DOAC users was calculated. Segmented regression was used to evaluate changes in mortality associated with the widespread adoption of DOACs (intervention point: 2014). Results: From 2010 to 2020, U.S. age-adjusted GI bleeding mortality rose from 0.6 to 1.3 per 100,000 population as DOAC use expanded to 72% of anticoagulant prescriptions. In contrast, exposure-adjusted mortality among DOAC users declined from 29.5 to 20.0 per 100,000 (2014–2020). Interrupted time-series analysis showed a significant pre-DOAC upward trend (p=0.047) but no significant post-DOAC slope change. A linear regression of 2014–2020 data demonstrated a near-significant decline (p=0.056), which reached significance when 2020 was excluded (p=0.014). Conclusions: Although the immediate and post-intervention changes in GI bleeding mortality after widespread DOAC adoption did not reach statistical significance, these findings are clinically reassuring: no detectable increase in fatal GI bleeding was observed at the population level. These results suggest that the transition to DOACs has not resulted in a large-scale increase in GI bleeding mortality. Future studies with larger datasets or pooled analyses will be important to confirm these trends and further define the population safety profile of DOACs.

Article activity feed